Psychosocial factors and treatment adherence in paediatric HIV/AIDS

S Naar-King1, C Arfken, M Frey

  • 1Wayne State University, USA. snaarkin@med.wayne.edu

AIDS Care
|July 13, 2006
PubMed

Insights

Caregiver substance use and HIV status significantly impact adherence to paediatric HIV treatment, affecting child health outcomes. Addressing these caregiver factors is crucial for improving treatment adherence and preventing disease progression in children with HIV.

Area of Science:

  • Social ecology
  • Public health
  • Pediatric infectious diseases

Background:

  • Non-adherence to treatment in pediatric HIV is a significant barrier to effective disease management.
  • Understanding the multifaceted factors influencing adherence is critical for improving child health outcomes.

Purpose of the Study:

  • To explore individual, familial, and extra-familial factors associated with caregiver adherence to pediatric HIV treatment.
  • To examine the relationship between these factors, caregiver adherence, and child health outcomes, specifically viral load.

Main Methods:

  • Cross-sectional study design involving 43 caregivers of children with HIV.
  • Data collected on individual, familial, and extra-familial factors, caregiver adherence, and child viral load from medical records.

Main Results:

  • Caregiver drug/alcohol use and HIV-positive status were linked to non-adherence and elevated viral load in children.
  • Negative outcome expectancy showed a trend towards lower adherence but was not statistically significant in multivariate analysis.
  • Extra-familial factors like dissatisfaction with care and stressful life events correlated with increased caregiver substance use.

Conclusions:

  • Caregiver substance use and HIV status are key predictors of non-adherence and poorer health outcomes in pediatric HIV.
  • Findings highlight the need for interventions targeting caregiver-specific factors to improve treatment adherence and child health.
  • Further research with larger samples is recommended to validate these findings and inform clinical practice.

Related Concept Videos

Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Amebiasis01:28

Amebiasis

Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...